Contenuto dell'articolo principale

Abstract

Introduction: The majority of patients with hormone receptor-positive breast cancer are treated with oral endocrine therapies, which are administered in periods ranging from 5 to 10 years. Adherence, ie the degree a subject's behavior corresponds to the agreed recommendations, then becomes a significant problem, which can also affect distress levels. The aim of this study is to evaluate the level of adherence to endocrine therapy and distress in a sample of Italian women.

Methods: The study is a descriptive cross sectional survey. Adherence was measured with the Morisky Medication Adherence 8-item Scale and distress was measured by the Distress Thermometer. Socio-demographic and clinical data were also collected and then processed.

Results: Adherence measured with MMAS-8 items scored 6.18 corresponding to an average level of adherence in the 151 patients examined. The only factors affecting adherence significantly were: level of education, marital status and, among the side effects of therapy, poor concentration and memory. The data analysis obtained from the Distress Thermometer showed a degree of discomfort equal to 4.71,For example, in younger patients' levels of distress are greater in relationships, whereas in married/defacto women and workers distress levels are greater in practical areas.

Conclusions: Results from this study can be useful to identify patients at risk for non-adherence and distress, and consequently to help, the oncology team. Despite this, the study of adherence and related-factors needs further investigation.

Keywords: Breastcancer, Endocrine Therapy, Adherence, Distress"ƒ

Aderenza alla terapia ormonale nelle donne con carcinoma mammario: uno studio quantitativo

Introduzione: La quasi totalití  delle pazienti con carcinoma mammario positivo ai recettori ormonali, viene trattata con terapie endocrine orali, da assumere per periodi che variano dai 5 ai 10 anni. L'aderenza, ossia il grado con il quale il comportamento di un soggetto corrisponde a quanto concordato con il medico, diviene quindi un problema rilevante, sul quale può incidere anche il Distress. L'obiettivo di questo studio è quello di valutare l'aderenza alla terapia endocrina ed il distress, in un campione di donne italiane.

Metodi: Nell'indagine quantitativa descrittiva, per la raccolta dati è stato utilizzato il questionario per l'aderenza MMAS-8-item, una scheda di raccolta dati socio-demografici-clinici ed il DistressThermometer. I dati sono stati elaborati mediante il programma SPSS.

Risultati: L'analisi dell'aderenza ha riportato, per le 151 pazienti prese in esame, un indice medio pari a 6.18. E' inoltre emerso che il livello d'istruzione, lo stato civile e la difficoltí  di concentrazione/memoria, incidono sull'aderenza. L'analisi dei dati ottenuti dal DistressThermometer ha evidenziato un grado di disagio pari a 4.71 che, per esempio,nelle pazienti più giovani è maggiore nell'area relazionale, mentre nelle donne coniugate/conviventi e in quelle lavoratrici è maggiore nell'area pratica.

Conclusioni: Lo studio mette in evidenza come il campione risulti mediamente aderente e con un livello di distress medio-basso. Queste informazioni possono essere utili per identificare le pazienti a rischio di non-aderenza e di distress,ed aiutare, di riflesso, il team di oncologia. Nonostante questo, lo studio sull'aderenza e sui fattori ad essa correlati necessita di ulteriori indagini. Parole Chiave: Carcinoma Mammario, Terapia Endocrina, Aderenza, Distress

Dettagli dell'articolo

Come citare
Iacorossi, L., Gambalunga, F., Fabi, A., Giannarelli, D., Facchinetti, G., Piredda, M., & De Marinis, M. G. (2016). Adherence to hormone therapy in women with breast cancer: a quantitative study. PROFESSIONI INFERMIERISTICHE, 69(2). Recuperato da https://www.profinf.net/pro3/index.php/IN/article/view/248

Riferimenti

  • All, W. H. O. (2003). Adherence to Long-Term Therapies: Evidence for Action.
  • Banning, M. (2012). Adherence to adjuvant therapy in post"menopausal breast cancer patients: a review. European journal of cancer care, 21(1), 10-19.
  • Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007). Early discontinuation of tamoxifen.Cancer, 109(5), 832-839.
  • Barron, T. I., Connolly, R., Bennett, K., Feely, J., & Kennedy, M. J. (2007). Early discontinuation of tamoxifen.Cancer, 109(5), 832-839.
  • Baum, M., Buzdar, A., Cuzick, J., Forbes, J., Houghton, J., Howell, A., &Sahmoud, T. (2003). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer, 98(9), 1802-1810.
  • Bond, W. S., & Hussar, D. A. (1991). Detection methods and strategies for improving medication compliance. American Journal of Health-System Pharmacy, 48(9), 1978-1988.
  • Bulli, F., Miccinesi, G., Maruelli, A., Katz, M., &Paci, E. (2009). The measure of psychological distress in cancer patients: the use of Distress Thermometer in the Oncological Rehabilitation Center of Florence. Supportive care in cancer, 17(7), 771-779.
  • Burstein, H. J., Temin, S., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., ... & Stearns, V. (2014). Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. Journal of Clinical Oncology, 32(21), 2255-2269.
  • Chlebowski, R. T., & Geller, M. L. (2007). Adherence to endocrine therapy for breast cancer.Oncology, 71(1-2), 1-9.
  • Claxton, A. J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance.Clinical therapeutics, 23(8), 1296-1310.
  • Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., ... & Coates, A. S. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.New England Journal of Medicine, 350(11), 1081-1092.
  • De Geest, S., von Renteln-Kruse, W., Steeman, E., Degraeve, S., & Abraham, I. L. (1998). Compliance issues with the geriatric population: complexity with aging. The Nursing clinics of North America, 33(3), 467-480.
  • Demissie, S., Silliman, R. A., & Lash, T. L. (2001). Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. Journal of Clinical Oncology, 19(2), 322-328.
  • Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004).Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor"”positive breast cancer.Journal of Clinical Oncology, 22(16), 3309-3315.
  • Gessler, S., Low, J., Daniells, E., Williams, R., Brough, V., Tookman, A., & Jones, L. (2008). Screening for distress in cancer patients: is the distress thermometer a valid measure in the UK and does it measure change over time? A prospective validation study.Psycho"Oncology, 17(6), 538-547.
  • Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., ... & Livingston, R. B. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.New England Journal of Medicine, 349(19), 1793-1802.
  • Grassi, L., Johansen, C., Annunziata, M. A., Capovilla, E., Costantini, A., Gritti, P., ... &Bellani, M. (2013). Screening for distress in cancer patients. Cancer, 119(9), 1714-1721.
  • Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2005). Adherence beliefs among breast cancer patients taking tamoxifen.Patient education and counseling, 59(1), 97-102.
  • Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W. Y., ... &Neugut, A. I. (2010). Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of Clinical Oncology, JCO-2009.
  • Hoagland, A. C., Morrow, G. R., Bennett, J. M., &CarnrikeJr, C. L. (1983).Oncologists' views of cancer patient noncompliance.American Journal of Clinical Oncology, 6(2), 239-244.
  • Holland, J. C., Andersen, B., Breitbart, W. S., Buchmann, L. O., Compas, B., Deshields, T. L., ... & Greiner, C. B. (2013). Distress management. Journal of the National Comprehensive Cancer Network, 11(2), 190-209.
  • Iacorossi, L., Piredda, M., De Marinis, M.G. (2014). Adherence to oral administration of endocrine treatment for the patient with breast cancer: revision of literature. Review in Oncology, 2(1), 27-32.
  • Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007). Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Medical care, 45(5), 431-439.
  • Karmakar, M. (2013). Predicting adherence to aromatase inhibitor therapy in patients with breast cancer using protection motivation theory (Doctoral dissertation, University of Toledo).
  • Kelly, A., &Agius, C. R. (2006). Improving adherence to endocrine therapies: the role of advanced practice nurses. Oncology (Williston Park, NY), 20 (10 Suppl Nurse Ed), 50-54.
  • Kennedy, J., Tuleu, I., & Mackay, K. (2008). Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribed. Journal of Managed Care Pharmacy, 14(6), 553-560.
  • Lash, T. L., Fox, M. P., Westrup, J. L., Fink, A. K., & Silliman, R. A. (2006). Adherence to tamoxifen over the five-year course. Breast cancer research and treatment, 99(2), 215-220.
  • Lazzari, D. (2011). Psicologia Sanitaria e malattiacronica.Interventi evidence based e disease management. Pisa: PaciniMedica.
  • MacLaughlin, E. J., Raehl, C. L., Treadway, A. K., Sterling, T. L., Zoller, D. P., & Bond, C. A. (2005). Assessing medication adherence in the elderly. Drugs & aging, 22(3), 231-255.
  • Mathes, T., Jaschinski, T., & Pieper, D. (2014).Adherence influencing factors–a systematic review of systematic reviews.Archives of Public Health, 72(1), 37.
  • Mitchell, A. J., Chan, M., Bhatti, H., Halton, M., Grassi, L., Johansen, C., &Meader, N. (2011). Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. The lancet oncology, 12(2), 160-174.
  • Morisky, D. E., Ang, A., Krousel"Wood, M., & Ward, H. J. (2008).Predictive validity of a medication adherence measure in an outpatient setting.The Journal of Clinical Hypertension, 10(5), 348-354.
  • Morris, L. S., & Schulz, R. M. (1993). Medication compliance: the patient's perspective. Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy.
  • Murray, M. D., Morrow, D. G., Weiner, M., Tu, W., Deer, M. M., Brater, D. C., & Weinberger, M. (2004).A conceptual framework to study medication adherence in older adults.The American journal of geriatric pharmacotherapy, 2(1), 36-43.
  • Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., &Asnis-Alibozek, A. (2008). Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.Journal of Clinical Oncology, 26(4), 556-562.
  • Partridge, A. H., Wang, P. S., Winer, E. P., &Avorn, J. (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.Journal of Clinical Oncology, 21(4), 602-606.
  • Rosenberg, S. M., Stanton, A. L., Petrie, K. J., & Partridge, A. H. (2015). Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.The oncologist, 20(6), 598-604.
  • Ruddy, K., Mayer, E., & Partridge, A. (2009).Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59(1), 56-66.
  • Sedjo, R. L., & Devine, S. (2011). Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast cancer research and treatment, 125(1), 191-200.
  • Siegel, R. L., Miller, K. D., &Jemal, A. (2015). Cancer statistics, 2015. CA: a cancer journal for clinicians, 65(1), 5-29.
  • Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet"Tieulent, J., &Jemal, A. (2015). Global cancer statistics, 2012. CA: a cancer journal for clinicians, 65(2), 87-108.
  • Wickersham, K., Happ, M. B., & Bender, C. M. (2012). "Keeping the Boogie Man Away": Medication Self-Management among Women Receiving Anastrozole Therapy. Nursing research and practice, 2012.
  • Wickersham, K., Sereika, S. M., & Bender, C. M. (2013).Pretreatment predictors of short-term nonadherence to oral hormonal therapy for women with breast cancer. Nursing research, 62(4), 243.